Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch

To investigate the class‐dependent properties of anti‐viral IgM antibodies, we use membrane antigen capture activated cell sorting to isolate spike‐protein‐specific B cells from donors recently infected with SARS‐CoV‐2, allowing production of recombinant antibodies. We isolate 20, spike‐protein‐specific antibodies of classes IgM, IgG, and IgA, none of which shows any antigen‐independent binding to human cells. Two antibodies of class IgM mediate virus neutralization at picomolar concentrations, but this potency is lost following artificial switch to IgG. Although, as expected, the IgG versions of the antibodies appear to have lower avidity than their IgM parents, this is not sufficient to explain the loss of potency.

[1]  M. Seeger,et al.  Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance , 2022, EMBO reports.

[2]  B. Becher,et al.  Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia , 2022, Annals of neurology.

[3]  Larance Ronsard,et al.  Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses , 2021, Science Immunology.

[4]  R. Newman,et al.  Endophilin A2 regulates B‐cell endocytosis and is required for germinal center and humoral responses , 2021, EMBO reports.

[5]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[6]  G. Kochs,et al.  Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants , 2021, Nature Communications.

[7]  M. Beltramello,et al.  N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.

[8]  Peter D. Crompton,et al.  Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites , 2021, The Journal of experimental medicine.

[9]  M. Battegay,et al.  SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event , 2021, PLoS pathogens.

[10]  Larance Ronsard,et al.  Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses , 2021, bioRxiv.

[11]  C. Rice,et al.  Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.

[12]  M. Battegay,et al.  Epidemiology and precision of SARS‐CoV‐2 detection following lockdown and relaxation measures , 2020, Journal of medical virology.

[13]  J. Beeson,et al.  Complement Factors in COVID-19 Therapeutics and Vaccines , 2020, Trends in Immunology.

[14]  L. Carter,et al.  Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.

[15]  B. Keyt,et al.  Structure, Function, and Therapeutic Use of IgM Antibodies , 2020, Antibodies.

[16]  D. Lauffenburger,et al.  Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.

[17]  C. Rice,et al.  LY6E impairs coronavirus fusion and confers immune control of viral disease , 2020, Nature Microbiology.

[18]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[19]  G. Zimmer,et al.  Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes , 2020, Vaccines.

[20]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 , 2020, Cell Host & Microbe.

[21]  L. Pirofski,et al.  A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition , 2020, Cell Host & Microbe.

[22]  R. Wallis,et al.  Rationale for targeting complement in COVID‐19 , 2020, EMBO molecular medicine.

[23]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[24]  M. Malim,et al.  Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings , 2020, medRxiv.

[25]  Xiangxi Wang,et al.  Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection , 2020, bioRxiv.

[26]  Charlotte M. Deane,et al.  CoV-AbDab: the Coronavirus Antibody Database , 2020, bioRxiv.

[27]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[28]  B. Becher,et al.  GM-CSF and CXCR4 Define a T Helper Cell Signature in Multiple Sclerosis , 2019, Nature Medicine.

[29]  A. Koster,et al.  Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b , 2019, Proceedings of the National Academy of Sciences.

[30]  John M. Lindner,et al.  Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells , 2019, Front. Immunol..

[31]  G. Alter,et al.  Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine , 2019, Front. Immunol..

[32]  Honglin Chen,et al.  An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency , 2019, Theranostics.

[33]  S. Fortune,et al.  Beyond binding: antibody effector functions in infectious diseases , 2017, Nature Reviews Immunology.

[34]  Veronika Chromikova,et al.  Evaluating the bottlenecks of recombinant IgM production in mammalian cells , 2015, Cytotechnology.

[35]  J. Molloy,et al.  B Cells Use Mechanical Energy to Discriminate Antigen Affinities , 2013, Science.

[36]  R. Loh,et al.  Quantitative serum immunoglobulin tests. , 2013, Australian Family Physician.

[37]  Michael Meyer-Hermann,et al.  Germinal center B cells govern their own fate via antibody feedback , 2013, The Journal of experimental medicine.

[38]  A. Casadevall,et al.  Variable Region Identical Immunoglobulins Differing in Isotype Express Different Paratopes* , 2012, The Journal of Biological Chemistry.

[39]  Niels H. Wulff,et al.  Monte Carlo simulation of the Spearman-Kaerber TCID50 , 2012, Journal of Clinical Bioinformatics.

[40]  G. Zimmer,et al.  A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.

[41]  D. Fremont,et al.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. , 2009, Cell host & microbe.

[42]  Robert Gentleman,et al.  ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data , 2009, Bioinform..

[43]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[44]  Masanori Suzuki,et al.  EGassembler: online bioinformatics service for large-scale processing, clustering and assembling ESTs and genomic DNA fragments , 2006, Nucleic Acids Res..

[45]  J. Goldman,et al.  B Cell Ligand Discrimination Through a Spreading and Contraction Response , 2006, Science.

[46]  M. Oda,et al.  Segmental flexibility and avidity of IgM in the interaction of polyvalent antigens. , 2004, Molecular immunology.

[47]  M. Neuberger,et al.  B cells acquire antigen from target cells after synapse formation , 2001, Nature.

[48]  M. Neuberger,et al.  Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.

[49]  N. Dimmock,et al.  Mechanisms of neutralization of a nairovirus (Dugbe virus) by polyclonal IgG and IgM. , 1992, Journal of General Virology.

[50]  J. Larrick,et al.  Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. , 1988, Journal of immunology.